Functional Roles of CD133: More than Stemness Associated Factor Regulated by the Microenvironment
-
Published:2023-11-03
Issue:1
Volume:20
Page:25-51
-
ISSN:2629-3269
-
Container-title:Stem Cell Reviews and Reports
-
language:en
-
Short-container-title:Stem Cell Rev and Rep
Author:
Moreno-Londoño Angela Patricia, Robles-Flores MarthaORCID
Abstract
AbstractCD133 protein has been one of the most used surface markers to select and identify cancer cells with stem-like features. However, its expression is not restricted to tumoral cells; it is also expressed in differentiated cells and stem/progenitor cells in various normal tissues. CD133 participates in several cellular processes, in part orchestrating signal transduction of essential pathways that frequently are dysregulated in cancer, such as PI3K/Akt signaling and the Wnt/β-catenin pathway. CD133 expression correlates with enhanced cell self-renewal, migration, invasion, and survival under stress conditions in cancer. Aside from the intrinsic cell mechanisms that regulate CD133 expression in each cellular type, extrinsic factors from the surrounding niche can also impact CD33 levels. The enhanced CD133 expression in cells can confer adaptive advantages by amplifying the activation of a specific signaling pathway in a context-dependent manner. In this review, we do not only describe the CD133 physiological functions known so far, but importantly, we analyze how the microenvironment changes impact the regulation of CD133 functions emphasizing its value as a marker of cell adaptability beyond a cancer-stem cell marker.
Graphical Abstract
Funder
Universidad Nacional Autónoma de México
Publisher
Springer Science and Business Media LLC
Reference242 articles.
1. Hatina, J., Kripnerová, M., Houdek, Z., Pešta, M., & Tichánek, F. (2022). Pluripotency stemness and cancer: More questions than answers. Advances in Experimental Medicine and Biology, 1376, 77–100. https://doi.org/10.1007/5584_2021_663 2. Wang, H., Gong, P., Li, J., Fu, Y., Zhou, Z., & Liu, L. (2020). Role of CD133 in human embryonic stem cell proliferation and teratoma formation. Stem Cell Research & Therapy, 11(1), 208. https://doi.org/10.1186/s13287-020-01729-0 3. Roudi, R., Ebrahimi, M., Sabet, M. N., Najafi, A., Nourani, M. R., Fomeshi, M. R., Samadikuchaksaraei, A., Shariftabrizi, A., & Madjd, Z. (2015). Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells. Future Oncology, 11(17), 2383–2393. https://doi.org/10.2217/fon.15.174 4. Liu, C. L., Chen, Y. J., Fan, M. H., Liao, Y. J., & Mao, T. L. (2020). Characteristics of CD133-sustained chemoresistant cancer stem-like cells in human ovarian carcinoma. International Journal of Molecular Sciences, 21(18), 6467. https://doi.org/10.3390/ijms21186467 5. Jaksch, M., Múnera, J., Bajpai, R., Terskikh, A., & Oshima, R. G. (2008). Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Research, 68(19), 7882–7886. https://doi.org/10.1158/0008-5472.CAN-08-0723
|
|